The interaction between the expression of CD23 molecule on B- lymphocytes and the level of specific IgE against molecular components of pollen in atopic dermatitis patients with and without dupilumab therapy
Language English Country Great Britain, England Media print-electronic
Document type Journal Article
- Keywords
- Atopic dermatitis, B lymphocytes, CD23 molecule, dupilumab, molecular components, specific IgE,
- MeSH
- Allergens immunology MeSH
- Dermatitis, Atopic * immunology drug therapy MeSH
- B-Lymphocytes * immunology MeSH
- Adult MeSH
- Antibodies, Monoclonal, Humanized * therapeutic use MeSH
- Immunoglobulin E * blood immunology MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Pollen * immunology MeSH
- Receptors, IgE * metabolism immunology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Allergens MeSH
- dupilumab MeSH Browser
- Antibodies, Monoclonal, Humanized * MeSH
- Immunoglobulin E * MeSH
- Receptors, IgE * MeSH
The aim of the study here was to evaluate the association between expression of CD23 molecule on B-lymphocytes and the level of specific IgE to molecular components of birch, Bermuda grass, hazel pollen, timothy, and rye grass in atopic dermatitis (AD) patients (with and without dupilumab therapy). A total of 46 patients suffering from AD were included: 26 without dupilumab treatment and 20 with dupilumab treatment. Serum levels of specific IgE were measured by the components resolved diagnostic assay ALEX2 Allergy Xplorer, the expression of CD23 molecule on B-lymphocytes was evaluated with flow cytometry. For the statistical analysis, the Spearman's rank correlation coefficient was used. In patients treated with dupilumab, the higher association was observed between the expression of CD23 on B-lymphocytes and specific IgE to molecular components Bet v 1, Cor a 1.0103, Cor a 1.0401, and Phl p 1. This study demonstrated that the relationship between CD23 expression on B-lymphocytes and specific IgE to pollen molecular components varies depending on whether the patient was treated with dupilumab and the type of molecular component involved.
What is already known about this topic?It is not yet known whether the expression of molecule CD23 on B lymphocytes is related to the level of allergen-specific IgE antibodies in AD patients. It is also not yet known what role dupilumab may have on this receptor.What does this article add to our knowledge?The study investigated the relationship between CD23 expression on B lymphocytes and specific IgE levels to various pollen molecular components in patients with atopic dermatitis (AD), both with and without dupilumab treatment.How does this study impact current management guidelines?The study provides insights into how dupilumab influences IgE interactions and allergic inflammation, potentially guiding more targeted treatments for AD patients.The findings suggest that dupilumab therapy may be more effective in AD patients sensitized to specific molecular components like Bet v 1, Cor a 1.0103, Cor a 1.0401, and Phl p 1, due to its role in reducing inflammatory responses.
Department of Medical Biophysics Medical Faculty of Charles University Hradec Králové Czech Republic
References provided by Crossref.org
